Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Annual Meeting.

The Journal of rheumatology·2026
Same author

Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS).

Pharmacy (Basel, Switzerland)·2026
Same author

Multidisciplinary Management in Psoriasis: A Structured Approach for Early Comorbidity Detection and Referral.

Dermatology and therapy·2026
Same author

Frequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study.

Annals of the rheumatic diseases·2026
Same author

Management of the Impact of Psoriasis on Sexuality: Consensus Recommendations From the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology.

Actas dermo-sifiliograficas·2026
Same author

Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality.

Dermatology and therapy·2026

Related Experiment Video

Updated: Jun 23, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial

Matthias Augustin1, Steven R Feldman2, Richard B Warren3,4

  • 1Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.

JAMA Dermatology
|February 18, 2026
PubMed
Summary
This summary is machine-generated.

Bimekizumab significantly improved patient-reported outcomes for moderate to severe plaque psoriasis over three years. Switching to bimekizumab also enhanced quality of life for patients previously treated with secukinumab.

More Related Videos

Using a 1064-nm Picosecond Neodymium-Doped Yttrium Aluminum Garnet Laser for Periorbital Hyperpigmentation
04:43

Using a 1064-nm Picosecond Neodymium-Doped Yttrium Aluminum Garnet Laser for Periorbital Hyperpigmentation

Published on: May 23, 2025

895
Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

767

Related Experiment Videos

Last Updated: Jun 23, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K
Using a 1064-nm Picosecond Neodymium-Doped Yttrium Aluminum Garnet Laser for Periorbital Hyperpigmentation
04:43

Using a 1064-nm Picosecond Neodymium-Doped Yttrium Aluminum Garnet Laser for Periorbital Hyperpigmentation

Published on: May 23, 2025

895
Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

767

Area of Science:

  • Dermatology
  • Clinical Trials
  • Patient-Reported Outcomes

Background:

  • Patient-reported outcomes (PROs) are crucial for assessing treatment effectiveness in plaque psoriasis.
  • Integrating PROs with clinical measures provides a comprehensive view of treatment benefits.

Purpose of the Study:

  • To evaluate patient-reported outcomes (PROs) in patients with moderate to severe plaque psoriasis treated with bimekizumab.
  • To compare PROs between continuous bimekizumab treatment and secukinumab followed by bimekizumab switch.

Main Methods:

  • The BE RADIANT trial involved a 48-week double-blinded period and a 96-week open-label extension (OLE), totaling 3 years.
  • Patients received bimekizumab or secukinumab initially; at year 1, secukinumab patients switched to bimekizumab.
  • Psoriasis Symptoms and Impacts Measure (P-SIM), PASI, and DLQI scores were assessed throughout the study.

Main Results:

  • Bimekizumab treatment led to rapid and sustained improvements in itching, skin pain, and scaling compared to secukinumab at week 4 and year 1.
  • Higher rates of concurrent PASI 0 and DLQI 0/1 achievement were observed with bimekizumab.
  • Patients switching from secukinumab to bimekizumab showed improved outcomes, with high response rates maintained to year 3 for both groups.

Conclusions:

  • Bimekizumab demonstrates rapid and durable improvements in symptoms and quality of life for plaque psoriasis patients up to 3 years.
  • Clinical efficacy of bimekizumab translates into significant improvements in health-related quality of life.
  • Switching to bimekizumab offers benefits for patients previously treated with secukinumab.